Role of Cyclooxygenase-2 (COX-2) and Its Inhibition in Tumor Biology and Radiotherapy
暂无分享,去创建一个
[1] J. Masferrer,et al. COX-2 Inhibitors as Radiosensitizing Agents for Cancer Therapy , 2003, American journal of clinical oncology.
[2] K. Ang,et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. , 2002, International journal of radiation oncology, biology, physics.
[3] N. Hayashi,et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. , 2002, Cancer research.
[4] Miyuki Saito,et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. , 2002, The American journal of pathology.
[5] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[6] M. Zemel,et al. Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice , 2002 .
[7] Y. Bakhle. COX‐2 and cancer: a new approach to an old problem , 2001, British journal of pharmacology.
[8] H. Choy,et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] L. Milas,et al. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. , 2001, Seminars in radiation oncology.
[10] P. Harari,et al. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. , 2001, Seminars in radiation oncology.
[11] A. Dicker,et al. Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation , 2001, American journal of clinical oncology.
[12] Ming Li,et al. Induction of apoptosis by cyclo‐oxygenase‐2 inhibitor NS398 through a cytochrome C‐dependent pathway in esophageal cancer cells , 2001, International journal of cancer.
[13] H. Osada,et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis , 2001, Oncogene.
[14] A. Grothey,et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? , 2001, Journal of Cancer Research and Clinical Oncology.
[15] Li Zhu,et al. Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44* , 2001, The Journal of Biological Chemistry.
[16] S. Lippman,et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] J. Holden,et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[18] W. Kiefer,et al. Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.
[19] C. Houchen,et al. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[20] K. Seibert,et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.
[21] Y. Kawahito,et al. Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.
[22] I. Gibbs,et al. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. , 2000, International journal of radiation oncology, biology, physics.
[23] Bert Vogelstein,et al. Combinatorial chemoprevention of intestinal neoplasia , 2000, Nature Medicine.
[24] P. Jänne,et al. Chemoprevention of colorectal cancer. , 2000, The New England journal of medicine.
[25] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[26] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[27] F. Lang,et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] S. Cohn,et al. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. , 2000, Gastroenterology.
[29] S. Yamashina,et al. Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.
[30] R. DuBois,et al. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. , 2000, Gastroenterology.
[31] M. Hull,et al. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. , 2000, European journal of cancer.
[32] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[33] P. Tofilon,et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. , 2000, Cancer research.
[34] K. Ang,et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] L. Howells,et al. Modulation of signal-transduction pathways by chemopreventive agents. , 2000, Biochemical Society transactions.
[36] Li Zhu,et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.
[37] E. Fosslien. Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia , 2000, Critical reviews in clinical laboratory sciences.
[38] K. Sheahan,et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. , 1999, JAMA.
[39] J. Masferrer,et al. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. , 1999, Expert opinion on investigational drugs.
[40] K. Sankaranarayanan,et al. In vivo and in vitro radioprotective effects of the prostaglandin E1 analogue misoprostol in DNA repair-proficient and -deficient rodent cell systems. , 1999, Radiation research.
[41] R. Gaynor,et al. Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.
[42] P. Tofilon,et al. Enhancement of Tumor Response to γ-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme , 1999 .
[43] R. Weichselbaum,et al. Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .
[44] J. Morrow,et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.
[45] Y. Yatabe,et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] T. Fahey,et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. , 1999, Cancer research.
[47] J. Shah,et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. , 1999, Cancer research.
[48] H. Shiozaki,et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma , 1999, American Journal of Gastroenterology.
[49] C. Hawkey,et al. COX-2 inhibitors , 1999, The Lancet.
[50] R. Weichselbaum,et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. , 1998, Cancer research.
[51] A. Ristimäki,et al. Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.
[52] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.
[53] A. Rojiani,et al. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. , 1998, International journal of radiation oncology, biology, physics.
[54] Y. Yatabe,et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.
[55] S. Meltzer,et al. Advances in Brief Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett ' s Esophagus and Associated Adenocarcinomas 1 , 2006 .
[56] A. Watson,et al. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. , 1998, Histology and histopathology.
[57] Li Zhu,et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.
[58] K. Seibert,et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.
[59] K. Kinzler,et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[60] Barry M. Forman,et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .
[61] R. Kerbel,et al. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. , 1996, European journal of cancer.
[62] Raymond L. White,et al. Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2 , 1996, Cell.
[63] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[64] R. Garavito. The cyclooxygenase-2 stucture: new drugs for an old target? , 1996, Nature Structural Biology.
[65] R. DuBois,et al. Prostaglandin endoperoxide synthase: why two isoforms? , 1996, The American journal of physiology.
[66] B. Spiegelman,et al. 15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.
[67] R. DuBois,et al. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.
[68] L. Milas,et al. Eicosanoids and radiation. , 1995, European journal of cancer.
[69] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[70] L. Peters,et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. , 1995, Cancer research.
[71] S Jothy,et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.
[72] G. Strassmann,et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. , 1995, Journal of immunology.
[73] L. Marnett. Generation of mutagens during arachidonic acid metabolism , 1994, Cancer Metastasis Review.
[74] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[75] K. Umesono,et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[76] D. Braun,et al. Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy , 1994 .
[77] B. Rigas,et al. Altered eicosanoid levels in human colon cancer. , 1993, The Journal of laboratory and clinical medicine.
[78] N. Zaffaroni,et al. Differential effect of 9 beta-chloro-16, 16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. , 1993, Radiation research.
[79] F. Malkinson,et al. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. , 1992, International journal of radiation biology.
[80] B. Varnum,et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.
[81] A. Haimovitz-Friedman,et al. Radiation Damage in Endothelial Cells Autocrine Effects of Fibroblast Growth Factor in Repair of Updated , 2006 .
[82] R. Erikson,et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[83] K. Seibert,et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.
[84] L. Milas,et al. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. , 1990, Cancer research.
[85] L. Milas,et al. Radioprotection of hematopoietic tissues in mice by indomethacin. , 1990, Radiation research.
[86] W. Smith,et al. The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.
[87] L. Milas,et al. Increase in radioresponse of murine tumors by treatment with indomethacin. , 1988, Cancer research.
[88] L. Milas,et al. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. , 1988, Cancer research.
[89] A. Fulton. Interactions of natural effector cells and prostaglandins in the control of metastasis. , 1987, Journal of the National Cancer Institute.
[90] E. J. Ainsworth,et al. 16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. , 1985, Radiation research.
[91] W. Hanson,et al. 16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. , 1983, Radiation research.
[92] R. Auerbach,et al. PGE2 and Angiogenesis 1 , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[93] P. Gullino,et al. Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.
[94] E. Mihich,et al. Prostaglandin modulation of development of cell-mediated immunity in culture , 1980, Nature.
[95] R. Herberman,et al. Inhibition of murine natural killer cell activity by prostaglandins. , 1980, Journal of immunology.
[96] J. Levy,et al. The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. , 1980, Cellular immunology.
[97] A. Bennett,et al. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers [proceedings]. , 1979, British journal of pharmacology.
[98] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[99] Y. Kakeji,et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma , 2004, Breast Cancer Research and Treatment.
[100] S. Gately. The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.
[101] L. Marnett,et al. COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.
[102] P. Thompson,et al. Carcinogen substrate specificity of human COX-1 and COX-2. , 2001, Carcinogenesis.
[103] K. Ang,et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. , 1999, International journal of radiation oncology, biology, physics.
[104] O'Banion Mk. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999 .
[105] K. Schrör,et al. Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.
[106] K. Sankaranarayanan,et al. Differential radioprotective effects of misoprostol in DNA repair-proficient and -deficient or radiosensitive cell systems. , 1997, International journal of radiation biology.
[107] W. Wahli,et al. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.
[108] C. Coleman,et al. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts , 1996 .
[109] L. Milas,et al. Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. , 1992, Advances in space research : the official journal of the Committee on Space Research.
[110] T. Eling,et al. Xenobiotic metabolism by prostaglandin H synthase. , 1992, Pharmacology & therapeutics.
[111] A. Gilman,et al. G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.